2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02269436 (ClinicalTrials.gov) | January 2015 | 8/10/2014 | A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS | A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: sNN0029 infusion solution | Newron Sweden AB | NULL | Terminated | 18 Years | 75 Years | Both | 11 | Phase 1 | Belgium;Netherlands |
| 2 | NCT01999803 (ClinicalTrials.gov) | September 2014 | 22/11/2013 | A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS | A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution | Amyotrophic Lateral Sclerosis | Drug: sNN0029;Drug: Placebo | Newron Sweden AB | NULL | Terminated | 18 Years | 75 Years | Both | 15 | Phase 1 | Belgium;Netherlands |